SER recommendations on treatment of refractory Behçet's syndrome.

OBJECTIVE: To develop multidisciplinary recommendations based on available evidence and expert consensus for the therapeutic management of patients with refractory Behçet's syndrome (BS) (difficult to treat, severe resistant, severe relapse) to conventional treatment. METHODS: A group of experts identified clinical research questions relevant to the objective of the document. These questions were reformulated in PICO format (patient, intervention, comparison and outcome). Systematic reviews of the evidence were conducted, the quality of the evidence was evaluated following the methodology of the international working group Grading of Recommendations Assessment, Development, and Evaluation (GRADE). After that, the multidisciplinary panel formulated the specific recommendations. RESULTS: 4 PICO questions were selected regarding the efficacy and safety of systemic pharmacological treatments in patients with BS with clinical manifestations refractory to conventional therapy related to mucocutaneous and/or articular, vascular, neurological parenchymal and gastrointestinal phenotypes. A total of 7 recommendations were made, structured by question, based on the identified evidence and expert consensus. CONCLUSIONS: The treatment of most severe clinical manifestations of BS lacks solid scientific evidence and, besides, there are no specific recommendation documents for patients with refractory disease. With the aim of providing a response to this need, here we present the first official Recommendations of the Spanish Society of Rheumatology for the management of these patients. They are devised as a tool for assistance in clinical decision making, therapeutic homogenisation and to reduce variability in the care of these patients.

Recommendations for prevention of infection in systemic autoimmune rheumatic diseases.

OBJECTIVES: To develop recommendations for the prevention of infection in adult patients with systemic autoimmune rheumatic diseases (SARD). METHODS: Clinical research questions relevant to the objective of the document were identified by a panel of experts selected based on their experience in the field. Systematic reviews of the available evidence were conducted, and evidence was graded according to the Scottish Intercollegiate Guidelines Network criteria. Specific recommendations were made. RESULTS: Five questions were selected, referring to prevention of infection by Pneumocystis jirovecii with trimethoprim/sulfamethoxazole, primary and secondary prophylactic measures against hepatitis B virus, vaccination against human papillomavirus, vaccination against Streptococcus pneumoniae and vaccination against influenza virus, making a total of 18 recommendations, structured by question, based on the evidence found for the different SARD and/or expert consensus. CONCLUSIONS: There is enough evidence on the safety and efficacy of vaccinations and other prophylactic measures against the microorganisms reviewed in this document to specifically recommend them for patients with SARD.

Recommendations for prevention of infection in systemic autoimmune rheumatic diseases. / Recomendaciones SER sobre prevención de infección en enfermedades reumáticas autoinmunes sistémicas.

OBJECTIVES: To develop recommendations for the prevention of infection in adult patients with systemic autoimmune rheumatic diseases (SARD). METHODS: Clinical research questions relevant to the objective of the document were identified by a panel of experts selected based on their experience in the field. Systematic reviews of the available evidence were conducted, and evidence was graded according to the Scottish Intercollegiate Guidelines Network criteria. Specific recommendations were made. RESULTS: Five questions were selected, referring to prevention of infection by Pneumocystis jirovecii with trimethoprim/sulfamethoxazole, primary and secondary prophylactic measures against hepatitis B virus, vaccination against human papillomavirus, vaccination against Streptococcus pneumoniae and vaccination against influenza virus, making a total of 18 recommendations, structured by question, based on the evidence found for the different SARD and/or expert consensus. CONCLUSIONS: There is enough evidence on the safety and efficacy of vaccinations and other prophylactic measures against the microorganisms reviewed in this document to specifically recommend them for patients with SARD.

Aproximación bibliométrica a la producción científica reumatológica española durante el período 1997–2006 / A bibliometric approach to the Spanish scientific production on rheumatology during the 1997–2006 period

Fundamento y objetivo. Los estudios bibliométricos mostraron su utilidad en la evaluación de la producción científica, por lo que se evalúa la producción reumatológica española en el período de 1997 a 2006.MétodoSe crearon frases de búsqueda para las bases de datos utilizadas (PubMed, Science Citation Index [SCI], Índice Médico Español [IME]). El análisis se basó en los resultados de SCI con indicadores bibliométricos de producción científica, colaboración, tipo de documento, citas recibidas y factor de impacto (FI). Resultados La producción científica española en Reumatología, según la base bibliográfica, fue de 602 documentos en PubMed, 1.073 documentos en SCI, y 627 documentos en IME. La distribución geográfica es parecida a otros estudios (Madrid, Cataluña, Galicia). Los «items citables» (artículos y revisiones) aumentaron de 54 a 98 documentos y la colaboración internacional aumentó de 3 a 33 documentos, de 1997 a 2006. El FI para todos los documentos de 1997 a 2001 fue de 6,79 ± 0,54 y de 9,60 ± 1,24 para el período de 2002 a 2006.ConclusionesLa producción científica española reumatológica continúa el ascenso de estudios previos (AU)

Background Bibliometric studies have shown their usefulness in the evaluation of science. This methodology was adopted for the analysis of Spanish rheumatologic scientific production during 1997–2006.MethodsSearch phrases were constructed for databases (PubMed, Science Citation Index (SCI), Índice Médico Español (IME)). The analysis was based on the results of SCI with bibliometric indicators for scientific production, collaboration, type of document, times cited and the measure of impact factor (FI). Results The scientific production in Spanish rheumatology recovered 602 documents in PubMed, 1073 in ISI, 627 in IME. The mapping of scientific productivity is similar to other studies (Madrid, Cataluña, Galicia). The “items citables” (citable items, articles and reviews) raised 54 to 98 and the international collaboration raised 3 to 33 documents (1997–2006). The FI for all documents in 1997–2001 was=6,79±0,54 and during 2002–2006=9,60±1,24.ConclusionsThis confirms an upward trend in Spanish scientific production in rheumatology with regard to previous studies (AU)

[A bibliometric approach to the Spanish scientific production on rheumatology during the 1997-2006 period]. / Aproximación bibliométrica a la producción científica reumatológica española durante el período 1997-2006.

BACKGROUND: Bibliometric studies have shown their usefulness in the evaluation of science. This methodology was adopted for the analysis of Spanish rheumatologic scientific production during 1997-2006. METHODS: Search phrases were constructed for databases (PubMed, Science Citation Index (SCI), Índice Médico Español (IME)). The analysis was based on the results of SCI with bibliometric indicators for scientific production, collaboration, type of document, times cited and the measure of impact factor (FI). RESULTS: The scientific production in Spanish rheumatology recovered 602 documents in PubMed, 1073 in ISI, 627 in IME. The mapping of scientific productivity is similar to other studies (Madrid, Cataluña, Galicia). The "items citables" (citable items, articles and reviews) raised 54 to 98 and the international collaboration raised 3 to 33 documents (1997-2006). The FI for all documents in 1997-2001 was=6,79±0,54 and during 2002-2006=9,60±1,24. CONCLUSIONS: This confirms an upward trend in Spanish scientific production in rheumatology with regard to previous studies.

Tratamiento de la artritis reumatoide con anakinra: revisión sistemática / Treatment of rheumatoid arthritis with anakinra: a systematic review

Objetivo: Evaluar la eficacia y la seguridad del anakinra en el tratamiento de la artritis reumatoide (AR) mediante una revisión sistemática de la evidencia científica. Material y método: Búsqueda en MEDLINE, EMBASE y el registro de estudios Cochrane desde el año 2000 hasta febrero de 2006 según una estrategia prediseñada de perfil sensible que incluyó todos los estudios controlados y aleatorizados (ECA) que evaluaron la eficacia o la seguridad del anakinra en el tratamiento de la AR. Resultados: Se incluyó 4 estudios para evaluar la eficacia del anakinra y un estudio para evaluar su seguridad. En todas las mediciones de eficacia analizadas, se observó un efecto beneficioso del anakinra respecto a placebo y del anakinra + metotrexato (MTX) respecto a la monoterapia con MTX. La combinación de anakinra y etanercept no fue más eficaz que el etanercept en monoterapia y, en cambio, incrementó la incidencia de infecciones graves. La tasa de suspensiones por reacciones adversas al anakinra fue discretamente superior a la del placebo, si bien se puede considerar que el anakinra es un fármaco bien tolerado y seguro a corto plazo cuyo efecto adverso más frecuente es la inflamación local en el punto de inyección. Conclusiones: El anakinra es una alternativa eficaz y segura para tratar a corto plazo la AR. Esta revisión no permite extraer conclusiones sobre la eficacia y la seguridad de este fármaco a largo plazo (AU)

Objective: To perform a systematic review for evaluating efficacy and safety of anakinra in the treatment of rheumatoid arthritis (RA). Material and method: The MedLine, Embase, and Cochrane Library databases were searched from January 2000 to February 2006 by using a high sensitive search that included every randomised controlled trial (RCTs) or controlled trial (CTs) that evaluated either efficacy or safety of Anakinra for the treatment of RA. Results: The search identified four relevant studies to evaluate efficacy. Patients treated with anakinra achieved significantly better clinical responses than those treated with placebo. Anakinra combined with methotrexate provided significantly greater clinical benefit than methotrexate alone. Combination therapy with etanercept and anakinra provides no added benefit and an increased safety risk compared with etanercept alone. Results from a large, placebo-controlled safety study demonstrate that anakinra is safe and well tolerated. The most common adverse effect was a mild local inflammation over the puncture area. Conclusions: This review confirmed both the efficacy and the safety of anakinra in the short term for the treatment of RA. Anakinra provides adequate clinical responses without major safety problems. This systematic review does not allow us to conclude on Anakinra responses in the long term (AU)

[Treatment of rheumatoid arthritis with anakinra: a systematic review]. / Tratamiento de la artritis reumatoide con anakinra: revisión sistemática.

OBJECTIVE: To perform a systematic review for evaluating efficacy and safety of anakinra in the treatment of rheumatoid arthritis (RA). MATERIAL AND METHOD: The MedLine, Embase, and Cochrane Library databases were searched from January 2000 to February 2006 by using a high sensitive search that included every randomised controlled trial (RCTs) or controlled trial (CTs) that evaluated either efficacy or safety of Anakinra for the treatment of RA. RESULTS: The search identified four relevant studies to evaluate efficacy. Patients treated with anakinra achieved significantly better clinical responses than those treated with placebo. Anakinra combined with methotrexate provided significantly greater clinical benefit than methotrexate alone. Combination therapy with etanercept and anakinra provides no added benefit and an increased safety risk compared with etanercept alone. Results from a large, placebo-controlled safety study demonstrate that anakinra is safe and well tolerated. The most common adverse effect was a mild local inflammation over the puncture area. CONCLUSIONS: This review confirmed both the efficacy and the safety of anakinra in the short term for the treatment of RA. Anakinra provides adequate clinical responses without major safety problems. This systematic review does not allow us to conclude on Anakinra responses in the long term.